Clinical Trials Logo

Whooping Cough clinical trials

View clinical trials related to Whooping Cough.

Filter by:

NCT ID: NCT04036526 Recruiting - Whooping Cough Clinical Trials

A Phase 1/2 Clinical Trial of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine

Start date: June 4, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The study should be leaded as a randomized double-blind placebo-controlled comparative research of potency and safety of a GamLPV, a live intranasal Bordetella pertussis vaccine, using two dosing schedules and methods of application in healthy human volunteers. The study contains three periods: screening, inpatient hospitalization and follow-up.

NCT ID: NCT04023929 Recruiting - Prematurity Clinical Trials

Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody Assays

COMPAre
Start date: October 28, 2020
Phase:
Study type: Observational

This study is designed to allow cord blood sample collection from the cords of babies born in three gestational age windows: ≥37 gestational weeks, 32-36+6 gestational weeks and less than 32 gestational weeks to investigate whether the result obtained using a standard hSBA assay is comparable to that achieved using complement from a gestation matched population for meningococcal B and pertussis.

NCT ID: NCT03751514 Recruiting - Whooping Cough Clinical Trials

Bordetella Pertussis Colonisation Challenge Study

Periscope
Start date: May 22, 2017
Phase: N/A
Study type: Interventional

This is a prospective controlled human challenge study consisting of two phases; Phase A: Development of a B. pertussis human challenge model; pilot to establish the standard inoculum Phase B: Development of a modified B. pertussis human challenge model

NCT ID: NCT02821195 Recruiting - Hepatitis B Clinical Trials

Study of Sanofi Pasteur's DTaP-IPV Hep B-PRP-T Combined Vaccine in Infants Who Previously Received Hepatitis B Vaccine

Start date: April 2015
Phase: Phase 3
Study type: Interventional

Phase III, open, mono-center study in 177 infants who received a dose of Hep B vaccine at birth or within 1 month after birth. Infants will receive Sanofi Pasteur's DTaP-IPV-Hep B-PRP-T combined vaccine (study vaccine) at 2, 3, and 4 months of age. All subjects will provide blood samples for immunogenicity assessment at baseline (pre-vaccination) and at 30 days following the third vaccination. Regarding safety, solicited reactions and unsolicited non-serious adverse events (AEs) will be collected up to 7 days and up to 30 days after each vaccination, respectively. Serious adverse events (SAEs) will be collected throughout the study trial (from Visit 1 to Visit 4)

NCT ID: NCT01929473 Recruiting - Pertussis Infection Clinical Trials

Seroepidemiological Study of Pertussis and Other Infectious Diseases

Start date: September 2013
Phase: N/A
Study type: Observational

Serum samples will be corrected twice from the same youth subjects with one year interval. Seroincidence of pertussis will be estimated by the elevation of Ig-G-PT in paired sera from an identical individual. The relationship between the incidence and the demographic data or medical history of the subjects will be discussed.